Ib Vestergaard Klewe, PhD, did his undergraduate studies in mathematics and biochemistry. Enrolled in a graduate program on human biology at the University of Copenhagen, Denmark he conducted his first laboratory studies in the field of Alzheimer’s disease research at the Gladstone Institute of Neurological Disease in San Francisco. He then moved on to study the finer details of dopamine receptor signaling in collaboration between the University of Copenhagen and the pharmaceutical company Lundbeck. Dopamine receptors are important drug targets for the treatment of both Parkinson’s disease and schizophrenia, and from the time he earned his PhD degree in 2010, he has been working at Lundbeck focusing on discovering and validating new targets for the treatment of psychiatric and neurodegenerative diseases. Most recently he has been heading a group of scientists that aims to validate a new treatment principle in Parkinson’s disease.